Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of GFT505 80mg in reducing serum
Triglycerides (TG) and increasing High Density Lipoprotein Cholesterol (HDL-C) levels
compared with placebo in atherogenic dyslipidaemic patients with abdominal obesity, and to
assess the tolerability and safety of once-a-day administrations of oral doses of GFT505
during 28 days.